

# ASX Announcement | 19 November 2021 Althea Group Holdings (ASX:AGH)

### **Issuing of Securities**

19 November 2021: Australian pharmaceutical company Althea Group Holdings Limited (ASX:AGH) ('Althea' or 'the Company') wishes to provide an update in relation to rights and securities which it has issued.

On 15 November 2021, the Company issued 5,705,598 fully paid ordinary shares in relation to the acquisition of Peak Processing Solutions ('Peak'). The shares are the conversion of the exchangeable shares issued at the time Peak received its full suite of licenses from Health Canada, which were subject to a twelve-month restriction period before being able to be exercised.

Althea has also focused on building and retaining a strong executive management team with the skills, experience and commitment necessary to propel the Company toward its ultimate goal of becoming the market leader in the global medicinal cannabis industry. The Company has implemented a long-term incentive (performance) rights framework, which was approved by shareholders on 27 November 2019, and aims to reward participants for achieving organisational objectives and delivering shareholder value.

The Board has endorsed the issue of 1,366,881 rights that have been issued to executives and senior managers in relation to short-term incentives for FY21. These rights are subject to restrictions ranging from twelve to twenty-four months.

The Company also issued 352,131 rights to various key opinion leaders (healthcare professionals) for services rendered to Althea, in lieu of cash.

#### -ENDS-

# Authorised by: Robert Meissner, Company Secretary

#### For further information, please contact:

Althea Josh Fegan CEO & Managing Director M: 1300 70 20 20 E: contact@althea.life Media Enquiries Dan Francome Media Relations P: +613 9650 5096 E: dfrancome@althea.life Investor Relations Jane Morgan Investor Relations Partner M: +61 405 555 618 E: jm@janemorganmanagement.com.au

# Althea Group Holdings Limited (ASX:AGH)

Althea Group Holdings Ltd (ASX:AGH) is a global pharmaceutical company and supplier of medicinal cannabis. Althea also offers a range of education, access and management services to support eligible patients and healthcare professionals in navigating medicinal cannabis treatment pathways.

Althea Group Holdings Limited | ABN 78 626 966 943

A. Level 37, 360 Elizabeth Street, Melbourne, 3000, Victoria, Australia

facebook.com/altheacompany

E. info@althea.lifeP. 1300 70 20 20W. althea.life

(O) @altheacompany

🥑 @altheacompany



Althea currently operates within highly regulated medicinal cannabis markets including Australia, United Kingdom and Germany, with plans to expand into emerging markets throughout Asia and Europe.

To learn more, please visit: www.althea.life

# Althea Group Holdings Limited | ABN 78 626 966 943

A. Level 37, 360 Elizabeth Street, Melbourne, 3000, Victoria, Australia

# E. info@althea.lifeP. 1300 70 20 20W. althea.life

facebook.com/altheacompany

(O) @altheacompany